A Study of Hospital-at-Home for People Receiving Tarlatamab
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMemorial Sloan Kettering Cancer Center
About this trial
The purpose of this study is to find out whether a Hospital-at-Home (HaH) program is a more efficient way to monitor people's health after receiving tarlatamab than monitoring in the hospital (inpatient).
Eligibility criteria
Qualifiers
Diagnosis of extensive stage small cell lung carcinoma (ES-SCLC)
Treatment plan of commercially available tarlatamab monotherapy as standard of care
Patients must be 18 years of age or older
Eastern Cooperative Oncology Group (ECOG) performance status <2
Disqualifiers
Patients with a documented active infection prior to starting tarlatamab. This includes grade 3 or higher viral, bacterial, or fungal infection.
Patients with baseline dementia or cognitive barriers
Uncontrolled arrhythmias
Caregiver deemed inappropriate by treating physician
Trial design
Treatments tested in this trial
- Hospital-at-Home/HAH
Treatment groups
70 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov